Table 5.
Onset of COVID-19-associated symptoms in the patients, Bangladesh, 2020.
| Symptom | Group | 1st−4th day | 5th−10th day | 11th−14th day | After 14th day |
|---|---|---|---|---|---|
| Fever | Male (n = 285) | 277 (97.2%) | 8 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Female (n = 126) | 118 (93.6%) | 7 (5.6%) | 1 (0.8%) | 0 (0.0%) | |
| Total | 395 (96.1%) | 15 (3.6%) | 1 (0.2%) | 0 (0.0%) | |
| Exhaustion | Male (n = 268) | 243 (90.7%) | 18 (6.7%) | 4 (1.5%) | 3 (1.1%) |
| Female (n = 122) | 104 (85.2%) | 10 (8.2%) | 5 (4.1%) | 3 (2.5%) | |
| Total | 347 (89.0%) | 28 (7.2%) | 9 (2.3%) | 6 (1.5%) | |
| Runny nose | Male (n = 60) | 49 (81.7%) | 11(18.3%) | 0 (0.0%) | 0 (0.0%) |
| Female (n = 35) | 28 (80.0%) | 5(14.3%) | 2 (5.7%) | 0 (0.0%) | |
| Total | 77 (81.0%) | 16 (16.8%) | 2 (2.1%) | 0 (0.0%) | |
| Cough | Male (n = 207) | 183 (88.4%) | 20 (9.7%) | 4 (1.9%) | 0 (0.0%) |
| Female (n = 104) | 91 (87.5%) | 10 (9.6%) | 3 (2.9%) | 0 (0.0%) | |
| Total | 274 (88.1%) | 30 (9.6%) | 7 (2.2%) | 0 (0.0%) | |
| Sore throat | Male (n = 183) | 165 (90.2%) | 16 (8.7%) | 1 (0.5%) | 1 (0.5%) |
| Female (n = 96) | 86 (89.6%) | 9 (9.4%) | 0 (0.0%) | 1 (1.0%) | |
| Total | 251 (90.0%) | 25 (9.0%) | 1 (0.4%) | 2 (0.7%) | |
| Shortness of breath | Male (n = 128) | 44 (34.4%) | 78 (60.9%) | 3 (2.3%) | 3 (2.3%) |
| Female (n = 65) | 22 (33.8%) | 37 (56.9%) | 4 (6.1%) | 2 (3.1%) | |
| Total | 66 (34.2%) | 115 (59.6%) | 7 (3.6%) | 5 (2.6%) | |
| Body ache | Male (n = 196) | 180 (91.8%) | 13 (6.6%) | 1 (0.5%) | 2 (1.0%) |
| Female (n = 79) | 73 (92.4%) | 6 (7.6%) | 0 (0.0%) | 0 (0.0%) | |
| Total | 253 (92.0%) | 19 (6.9%) | 1 (0.4%) | 2 (0.7%) | |
| Diarrhea | Male (n = 95) | 76 (80.0%) | 15 (15.8%) | 4 (4.2%) | 0 (0.0%) |
| Female (n = 40) | 32 (80.0%) | 6 (15.0%) | 2 (5.0%) | 0 (0.0%) | |
| Total | 108 (80.0%) | 21 (15.6%) | 6 (4.4%) | 0 (0.0%) | |
| Loss of taste | Male (n = 201) | 71 (35.3%) | 128 (63.7%) | 2 (1.0%) | 0 (0.0%) |
| Female (n = 80) | 34 (42.5%) | 45 (56.2%) | 1 (1.2%) | 0 (0.0%) | |
| Total | 105 (37.4%) | 173 (61.6%) | 3 (1.1%) | 0 (0.0%) | |
| Loss of smell | Male (n = 162) | 67 (41.4%) | 89 (54.9%) | 6 (3.7%) | 0 (0.0%) |
| Female (n = 56) | 18 (32.1%) | 35 (62.5%) | 3 (5.4%) | 0 (0.0%) | |
| Total | 85 (39.0%) | 124 (56.9%) | 9 (4.1%) | 0 (0.0%) | |
| Vomiting | Male (n = 51) | 35 (68.6%) | 14 (27.4%) | 1 (2.0%) | 1 (2.0%) |
| Female (n = 35) | 27 (77.1%) | 5 (14.3%) | 1 (2.9%) | 2 (5.7%) | |
| Total | 62 (72.1%) | 19 (22.1%) | 2 (2.3%) | 3 (3.5%) | |
| Headache | Male (n = 101) | 89 (88.1%) | 11 (10.9%) | 0 (0.0%) | 1 (1.0%) |
| Female (n = 53) | 48 (90.6%) | 3 (5.7%) | 0 (0.0%) | 2 (3.8%) | |
| Total | 137 (89.0%) | 14 (9.1%) | 0 (0.0%) | 3 (1.9%) | |
| Digestive problems | Male (n = 41) | 26 (63.4%) | 12 (29.3%) | 1 (2.4%) | 2 (4.9%) |
| Female (n = 24) | 16 (66.7%) | 7 (29.2%) | 1 (4.2%) | 0 (0.0%) | |
| Total | 42 (64.6%) | 19 (29.2%) | 2 (3.1%) | 2 (3.1%) | |
| Lack of appetite | Male (n = 114) | 104 (91.2%) | 9 (7.9%) | 0 (0.0%) | 1 (0.9%) |
| Female (n = 59) | 51 (86.4%) | 6 (10.2%) | 2 (3.4%) | 0 (0.0%) | |
| Total | 155 (89.6%) | 15 (8.7%) | 2 (1.2%) | 1 (0.6%) | |
| Rashes | Male (n = 31) | 17 (54.8%) | 12 (38.7%) | 2 (6.4%) | 0 (0.0%) |
| Female (n = 13) | 9 (69.2%) | 1 (7.7%) | 3 (23.1%) | 0 (0.0%) | |
| Total | 26 (59.1%) | 13 (29.5%) | 5 (11.4%) | 0 (0.0%) | |
| Blistering | Male (n = 7) | 4 (57.1%) | 1 (14.3%) | 0 (0.0%) | 2 (28.6%) |
| Female (n = 3) | 2 (66.7%) | 1 (33.3%) | 0 (0.0%) | 0 (0.0%) | |
| Total | 6 (60.0%) | 2 (20.0%) | 0 (0.0%) | 2 (20.0%) | |
| Confusion | Male (n = 62) | 23 (37.1%) | 21 (33.9%) | 15(24.2%) | 3 (4.8%) |
| Female (n = 28) | 5 (17.9%) | 10 (35.7%) | 9 (32.1%) | 4 (14.3%) | |
| Total | 28 (31.1%) | 31 (34.4%) | 24 (26.7%) | 7 (7.8%) | |
| Loss of speech | Male (n = 43) | 18 (41.9%) | 16 (37.2%) | 8 (18.6%) | 1 (2.3%) |
| Female (n = 15) | 4 (26.7%) | 1 (6.7%) | 2 (13.3%) | 8 (53.3%) | |
| Total | 22 (37.9%) | 24 (41.4%) | 10 (17.2%) | 2 (3.4%) |
Values are expressed as frequency and % response of the final respondents. The percentage was calculated considering the samples in the individual groups.